Two different FAK inhibitors (PF-562271 and GSK2256098C) in the Genomics of Drug Sensitivity in Cancer (GDSC) cell line drug screening database showed no relationship with cilengitide sensitivity (-0.39 and -0.18, respectively and neither was statistically significant using the available samples, Supp. This evidence concerns the gene PTK2 and cancer.